Treatment of Severe Postmenopausal Endometriosis With an Aromatase Inhibitor

Kazuto Takayama, Takayama K, K Takayama, Zeitoun K, Khaled Zeitoun, K Zeitoun, Robert T. Gunby, Gunby RT, R T Gunby, Hironobu Sasano, Sasano H, H Sasano, Bruce R. Carr, Carr BR, B R Carr, S E Bulun, Serdar E. Bulun, Bulun Se
Fertility and sterility · 1998 · vol. 69(4) , pp. 709–713 · doi:10.1016/s0015-0282(98)00022-3 · PMID:9548162 · W2092919766
article OA: closed CC0 ⤵ 204 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This paper investigated the use of an aromatase inhibitor for treating severe postmenopausal endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

ObjectiveTo treat an unusually aggressive case of recurrent postmenopausal endometriosis.DesignCase report.SettingUniversity of Texas Southwestern Medical Center (Dallas, Texas).Patient(s)A 57-year-old woman who presented with recurrent severe endometriosis after hysterectomy and bilateral salpingo-oophorectomy.Intervention(s)Oral administration of anastrozole (an aromatase inhibitor) (1 mg/d) and elemental calcium (1.5 g/d) for 9 months. Alendronate (a nonestrogenic inhibitor of bone resorption), 10 mg/d, was added to this regimen.Main outcome measure(s)Reduction in size of endometriotic lesion, pain relief, tissue levels of aromatase P450 messenger RNA, bone density.Result(s)Circulating levels of estradiol-17beta were reduced to approximately 50% of the baseline value after the onset of treatment with anastrozole. Pain rapidly decreased and completely disappeared after the 2nd month of treatment. The 30 x 30 x 20-mm bright red polypoid vaginal lesion was reduced to a 3-mm gray tissue by the end of 9 months of treatment. Markedly high pretreatment levels of aromatase P450 messenger RNA in the endometriotic tissue became undetectable in a specimen obtained from a repeated biopsy after 6 months of treatment. Bone density of lumbar spine decreased by 6.2% after 9 months of treatment.Conclusion(s)This is the first description of the use of an aromatase inhibitor in the treatment of endometriosis. The short-term results were extraordinarily successful in elimination of pain and near-complete eradication of implants associated with severe endometriosis not responsive to other therapy. We conclude that the recently developed potent aromatase inhibitors are candidate drugs in the treatment of endometriosis that is resistant to standard regimens.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Aromatase Inhibitors Endometriosis Enzyme Inhibitors Nitriles Postmenopause Triazoles Administration, Oral Anastrozole Animals Aromatase Aromatase Aromatase Biopsy Endometriosis Endometriosis Enzyme Inhibitors Enzyme Inhibitors Female Humans Middle Aged

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (23)

Cited by (50)

Source provenance

europepmc
last seen: 2026-08-08T06:08:32.324769+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:10:40.754221+00:00
License: CC0 · commercial use OK